Dublication cump						
Publication summary						
Title	The impact of an enteral formula with food-derived ingredients on dietetic practice at a specialist children's hospital in the UK:  Retrospective study					
Authors	Graeme O'Connor, Angela Camacho Velandia, Zoltan Hartfiel Capriles					
Publication date + magazine	Journal of Human Nutrition and Dietetics 2024;1-9					
Type of study	Single - centre retrospective study					
Objective / hypothesis	Monitor the implementation of enteral formulas with food - derived ingredients (EFI) by dietitians in a specialist children's hospital.					
Results	Types of patients  - Multiple acute and chronic conditions were included at this specialist hospital centre  - Most common primary diagnosis neurological followed by cardiac, gastrointestinal, oncology, metabolic, renal, endocrine, ENT and respiratory  - The data includes children as inpatient and community patients.  Age groups  - Compleat® paediatric used in 21 (30%) young children aged 1–3 years and 4 (6%) adolescence aged 16–18 years  Method of feeding and duration  - Continuous feeding in 41 (59%) children & 27 (38%) children bolus feeding. The bolus data can support the use of Simplink in your markets.  - Administration effective with PEG users= 36 (51%) children, PEG-Jextension users = 3 (4%) children, JEJ users= 2 (3%) children. Please note some children are sensitive, so it still needs a medical/dietetic review to make this decision  - 23/70 (33%) children established on Compleat® paediatric for 1–6 months, 14/70 (20%) children for more than 1 year. Please refer to table 7.  - 19/42 (45%) children were discharged onto Compleat® paediatric as home care patients  GI symptoms  - 58/70 (83%) inpatient children switched to Compleat® paediatric, with 42/58 (82%) saw improvements in GI symptoms.  - Similar trends seen for gastrointestinal symptoms improved within 7 days after Compleat® paediatric was started. Loose stools 20/22 (90%), constipation 12/15 (73%), vomiting 6/8 (75%), abdominal discomfort 5/7 (71%), reflux 3/5 (60%), high stoma output 1/1 (100%), please refer to table 4 (screenshot below).					



	TABLE 4 Outlines the and after commencing are ingredients (within 7 days)  Gastrointestinal Symptom  Loose stools  Constipation  vomiting  Abdominal discomfort  Reflux  High stoma output	enteral for	Reported improvement in symptoms within 7 days after feed started, n (%) 20/22 (90) 12/15 (73) 6/8 (75) 5/7 (71) 3/5 (60) 1 (100)		
Conclusion	<ol> <li>Recommendations:</li> <li>Use as 1<sup>st</sup> line therapy with no underlying gastrointestinal symptoms</li> <li>Use in an acute clinical setting as a compromise when parents ask for home-made blended diets</li> <li>Use for children with GI symptoms and not tolerating current tube feed</li> </ol>				
Methods	<ul> <li>The retrospective data was collected on 70 children between August 2022 and December 2023.</li> <li>Children's clinical and dietetic information was collected from the hospital's electronic records</li> <li>Data on demographics (age, sex and primary diagnosis), anthropometric measurements (weight-for-age Z-score and height-for-age Z-score), feed regimens (feed volume, feeding route and mode of feeding [continuous, bolus]) and gastrointestinal symptoms (gastro-oesophageal reflux, vomiting, abdominal discomfort [bloating/flatulence], constipation and loose stools) was collected using Microsoft forms.</li> </ul>				
Limitations	Retrospective design > only potential associations that an EFI may improve GI symptoms.				

